Top Page
Imagion Biosystems Ltd.
(Sydney:IBX)
Imagion Biosystems Ltd. (IBX) vs. iShares MSCI Australia ETF (EWA)
Imagion Biosystems Ltd. Business Overview & Revenue Model
Imagion Biosystems Ltd. Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 2.67M | 1.08M | 473.43K | 232.87K |
| Gross Profit | -8.81K | 2.26M | -279.83K | -3.14M | -2.47M |
| EBITDA | -3.58M | -700.09K | -10.30M | -11.03M | -5.62M |
| Net Income | -4.31M | -2.07M | -12.47M | -9.81M | -6.02M |
Balance Sheet | |||||
| Total Assets | 2.04M | 2.80M | 4.59M | 9.98M | 14.12M |
| Cash, Cash Equivalents and Short-Term Investments | 1.85M | 2.67M | 227.08K | 4.45M | 13.39M |
| Total Debt | 2.56M | 2.85M | 6.04M | 4.60M | 46.02K |
| Total Liabilities | 4.21M | 5.09M | 8.37M | 5.30M | 809.88K |
| Stockholders Equity | -2.16M | -2.28M | -3.79M | 4.68M | 13.31M |
Cash Flow | |||||
| Free Cash Flow | -4.04M | -1.27M | -8.51M | -9.21M | -5.29M |
| Operating Cash Flow | -4.04M | -1.27M | -8.32M | -8.70M | -5.07M |
| Investing Cash Flow | 0.00 | 83.74K | -190.38K | -468.73K | -310.09K |
| Financing Cash Flow | 3.24M | 3.61M | 4.29M | -962.06K | 5.15M |
Imagion Biosystems Ltd. Technical Analysis
Imagion Biosystems Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | AU$56.13M | 10.72 | 72.82% | ― | 11.93% | 2.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$195.44M | -7.39 | -164.12% | ― | 12.96% | 40.81% | |
43 Neutral | AU$10.30M | -1.61 | 142.99% | ― | -47.02% | 94.37% | |
42 Neutral | AU$33.92M | -2.45 | -164.22% | ― | ― | 23.85% | |
38 Underperform | AU$46.46M | -3.02 | -37.14% | ― | 2.33% | 12.50% |
Imagion Biosystems Ltd. Corporate Events
Imagion Biosystems reported no revenue from ordinary activities for the year ended 31 December 2025, with its net loss after tax widening 108.5% to $4.31 million compared with the prior year. The company’s net tangible assets per share improved from negative 1.11 cents to negative 0.44 cents, no dividends were declared for either year, and its audited financial statements received an unmodified opinion, indicating clean audit assurance despite ongoing operating losses.
The group reported no changes in control over subsidiaries, no associates or joint ventures, and confirmed that its U.S. subsidiary continues to report under IFRS in line with Australian standards. The 2025 annual report has been released to provide further detail on operations and financial performance, underscoring the company’s continued investment phase and the absence of near‑term shareholder returns through dividends.
The most recent analyst rating on (AU:IBX) stock is a Buy with a A$0.03 price target. To see the full list of analyst forecasts on Imagion Biosystems Ltd. stock, see the AU:IBX Stock Forecast page.
Imagion Biosystems has submitted its first Investigational New Drug application to the U.S. Food and Drug Administration for its MagSense® HER2 imaging agent, a key step toward launching a Phase 2 clinical trial in HER2-positive breast cancer across multiple U.S. sites as early as the first quarter of 2026. The Phase 2 trial, designed in three parts and expected to run for 18–24 months after FDA acceptance, will further assess safety, refine dosing and imaging protocols, and evaluate diagnostic performance, while also generating data on economic impact, patient outcomes and AI-enabled quantitative imaging; with strategic trial partners already engaged and site preparations under way, the milestone signals operational readiness and advances Imagion’s efforts to validate its platform and strengthen its position in cancer imaging.
The most recent analyst rating on (AU:IBX) stock is a Buy with a A$0.03 price target. To see the full list of analyst forecasts on Imagion Biosystems Ltd. stock, see the AU:IBX Stock Forecast page.
Imagion Biosystems has completed manufacturing and independent analytical testing of its MagSense® HER2 Imaging Agent, clearing a key technical hurdle toward filing an Investigational New Drug application with the U.S. FDA in the first quarter of 2026 for a planned Phase 2 clinical trial. A collaboration with MRI specialists at Wayne State University produced an optimized imaging protocol that allows for a one‑third dose reduction versus the Phase 1 trial and improved MRI sequence selection, changes that could enhance patient safety, image quality, and the agent’s clinical adoption prospects; in parallel, the company strengthened its U.S. leadership by appointing former Chief Business Officer Ward Detwiler as president of its U.S. subsidiary to drive growth and operational development.
The most recent analyst rating on (AU:IBX) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Imagion Biosystems Ltd. stock, see the AU:IBX Stock Forecast page.
Imagion Biosystems has issued 3,048,484 new fully paid ordinary shares at a deemed price of 2.5 cents each following the conversion of 76,212 convertible notes held under its agreement with Mercer Street Global Opportunity Fund, LLC, leaving Mercer with a remaining balance of 2,750,000 convertible notes. In conjunction with the cleansing notice provided under Section 708A of the Corporations Act, the board reiterated that it expects to lodge its IND submission for the HER2+ Phase 2 clinical trial with the US FDA in the near term, signalling ongoing progress in its clinical development pipeline while maintaining compliance with continuous disclosure obligations.
The most recent analyst rating on (AU:IBX) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Imagion Biosystems Ltd. stock, see the AU:IBX Stock Forecast page.
Imagion Biosystems Limited has applied to the ASX for quotation of 3,048,484 new fully paid ordinary shares, issued on 8 January 2026 following the exercise of options or conversion of other securities. The additional quotation expands the company’s listed capital base and may modestly enhance liquidity in its shares, signalling ongoing utilisation of existing equity-based instruments and incremental capital formation that could support its operational and development activities.
The most recent analyst rating on (AU:IBX) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Imagion Biosystems Ltd. stock, see the AU:IBX Stock Forecast page.
Imagion Biosystems has completed the conversion of the remaining first tranche of its convertible notes with Mercer Street Global Opportunity Fund, issuing 3,048,484 ordinary shares and fully extinguishing the A$1.65 million tranche, thereby simplifying its capital structure. The company has also renegotiated terms on the A$1.1 million second tranche, making a A$300,000 payment to reduce the outstanding balance to A$558,000, extending the maturity to 28 February 2026, and agreeing that any remaining balance at that date will be mandatorily converted into shares at the contractual conversion price, signalling continued support from Mercer Street and providing greater visibility over Imagion’s near-term financing as it advances its MagSense® cancer imaging technology.
The most recent analyst rating on (AU:IBX) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Imagion Biosystems Ltd. stock, see the AU:IBX Stock Forecast page.
Imagion Biosystems has disclosed a change in director Robert Romeo Proulx’s interests, with the acquisition of 1.4 million ordinary shares and the lapse or disposal of 1.4 million unlisted performance rights tied to market capitalisation milestones. The reshaping of Proulx’s holdings, which now tilt more toward ordinary equity and away from certain performance-based rights, may slightly alter the incentive mix for the director but does not signal a change to the company’s broader operational or clinical strategy.
The most recent analyst rating on (AU:IBX) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Imagion Biosystems Ltd. stock, see the AU:IBX Stock Forecast page.
Imagion Biosystems has issued 1.4 million fully paid ordinary shares at a deemed price of 2.2 cents each following the vesting of performance rights granted to Executive Chairman Robert Proulx, and has lodged a cleansing notice under Section 708A of the Corporations Act to confirm the shares were issued without a disclosure document and that the company remains compliant with its continuous disclosure and reporting obligations. The board also reiterated that, consistent with prior disclosures, the Phase 2 clinical trial Investigational New Drug submission for its HER2+ program is expected to be filed with the US Food and Drug Administration in the near term, signalling progress in its clinical development pipeline alongside modest equity issuance to management.
The most recent analyst rating on (AU:IBX) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Imagion Biosystems Ltd. stock, see the AU:IBX Stock Forecast page.
Imagion Biosystems Limited has applied to the ASX for quotation of 1.4 million new ordinary fully paid shares, to be traded under its existing ticker symbol IBX. The new securities, issued on 29 December 2025 following the exercise or conversion of existing options or other convertible securities, modestly increase the company’s listed share capital and provide additional liquidity for shareholders, though the announcement does not disclose any broader strategic or operational changes tied to this issuance.
The most recent analyst rating on (AU:IBX) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Imagion Biosystems Ltd. stock, see the AU:IBX Stock Forecast page.